| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 07/24/2013 | EP2617829A1 Synthetic gene for expressing sm-14 in pichia pastoris, methods for producing and purifying sm-14 and the use thereof as a vaccine and diagnostic medium |
| 07/24/2013 | EP2617433A2 Treatment of neurodegenerative diseases by targeting mirna |
| 07/24/2013 | EP2617432A1 Brain function enhancement composition and method for enhancing brain function |
| 07/24/2013 | EP2617431A2 Polypeptide inhibitors of HSP27 kinase and uses therefor |
| 07/24/2013 | EP2617430A1 Composition for improving brain function and method for improving brain function |
| 07/24/2013 | EP2617413A2 Nano-vehicle derived from tumor tissue, and cancer vaccine using same |
| 07/24/2013 | EP2616485A2 Step-derived peptide for brain injury treatment |
| 07/24/2013 | EP2616480A1 Peptide inhibitors of cd40l signaling and uses therefor |
| 07/24/2013 | EP2616478A2 Anti-heparan sulfate peptides that block herpes simplex virus infection in vivo |
| 07/24/2013 | EP2616096A1 Treatment of vascular diseases using encapsulated cells encoding and secreting glp-1, or a fragment or variant thereof |
| 07/24/2013 | EP2616095A2 Acceleration of wound healing by growth hormone releasing hormone and its agonists |
| 07/24/2013 | EP2616094A2 Treatment of penetrative injury to the brain |
| 07/24/2013 | EP2616093A2 Broad spectrum antibiotic arylomycin analogs |
| 07/24/2013 | EP2616092A1 Treatment of chronic nephropathies using soluble complement receptor type i (scr1) |
| 07/24/2013 | EP2616091A1 Stabilization of immunoglobulins and other proteins through aqueous formulations with sodium chloride at weak acidic to neutral ph |
| 07/24/2013 | EP2616090A1 Stabilization of immunoglobulins through aqueous formulation with histidine at weak acidic to neutral ph |
| 07/24/2013 | EP2616054A2 Therapy for mll-rearranged leukemia |
| 07/24/2013 | EP2616048A1 Preparation and use of combination enzyme and gastrointestinal modulator delivery systems |
| 07/24/2013 | CN1984664B Methods for treating bleeding disorders using sulfated polysaccharides |
| 07/24/2013 | CN1853730B Modified cytokines for use in cancer therapy |
| 07/24/2013 | CN1822845B Means for preventing and treating cellular death and their biological applications |
| 07/24/2013 | CN1462191B Treatment of ocute coronary syndrome with GLP-1 |
| 07/24/2013 | CN103221425A Fusion proteins comprising antigenic APOB-00 protein fragments and a protein carrier, related compositions, methods and systems for treatment and/or prevention of atherosclerosis |
| 07/24/2013 | CN103221424A Recombinant T-cell receptor ligands with covalently bound peptides |
| 07/24/2013 | CN103221066A Sustained-release pharmaceutical composition |
| 07/24/2013 | CN103221061A Factor II and fibrinogen for treatment of haemostatic disorders |
| 07/24/2013 | CN103221060A Tumor growth controlling method targeting galactosylceramide expression factor-1 |
| 07/24/2013 | CN103221053A New treatments of hepatitis c virus infection |
| 07/24/2013 | CN103221036A Enteric coated, low-strength pancrelipase formulations |
| 07/24/2013 | CN103221033A Compositions for gastric delivery of active agents |
| 07/24/2013 | CN103217534A Lung cancer marker SBP-1 and its application |
| 07/24/2013 | CN103215328A Transglutaminase mediated conjugation of peptides |
| 07/24/2013 | CN103215273A Protein CGREF1 inhibiting cell proliferation, and expression sequence and application thereof |
| 07/24/2013 | CN103215257A Protein for treating hemangioma |
| 07/24/2013 | CN103215194A Novel saccharomyces and application |
| 07/24/2013 | CN103214584A Fusion protein with double functions of inhibiting revascularization of tumor microenvironment and activating adaptive immune response, and gene and application thereof |
| 07/24/2013 | CN103214580A Anti Her2 immune cytokine and application thereof |
| 07/24/2013 | CN103214579A Animal fusion recombinant interferon |
| 07/24/2013 | CN103214569A Site-directed modification of fviii |
| 07/24/2013 | CN103214558A Antimicrobial polypeptides |
| 07/24/2013 | CN103214555A Peptide inhibitors for mediating stress responses |
| 07/24/2013 | CN103214552A Synthesis and application of multi-site modified endomorphin-1 analogue |
| 07/24/2013 | CN103214551A Preparation method and applications of auricularia polytricha blood fat reduction function protein extract |
| 07/24/2013 | CN103212093A Magnetic nano-grade material with cell-targeting property, and biomedical application thereof |
| 07/24/2013 | CN103212084A IgG FC fragment for a drug carrier and method for the preparation thereof |
| 07/24/2013 | CN103212077A Application of Erbin inhibitor in preparation of antitumor drug |
| 07/24/2013 | CN103212066A Preparation method of cyclobutane pyrimidine dimmer photolyase liposome |
| 07/24/2013 | CN103212065A Urease nano-reactor and preparation method thereof |
| 07/24/2013 | CN103212064A Application of phosphorylation-pathway-related factor in regulating regulatory T-cell function |
| 07/24/2013 | CN103212063A Treating dyspnea associated with acute heart failure by relaxin |
| 07/24/2013 | CN103212062A Preparation method of pig spleen transfer factor injection |
| 07/24/2013 | CN103212061A Application of free fatty acid receptor 2 in antitumor drugs |
| 07/24/2013 | CN103212060A Application of protein and composition thereof in preparation of product used for preventing, diagnosing or treating EHEC (Enterohemorrhagic Escherichia Coli) infection |
| 07/24/2013 | CN103212059A Composition containing antifungal drug and lactate buffering liquid |
| 07/24/2013 | CN103212058A Composition containing antifungal drug and lactate buffering agent |
| 07/24/2013 | CN103212057A Medical composition containing low-dosage desmopressin |
| 07/24/2013 | CN103212056A Preparation based on gold, silver, gold-silver mixture and glutathione/chitosan, and application of preparation |
| 07/24/2013 | CN103212055A Drug composition of bortezomib and preparation method thereof |
| 07/24/2013 | CN103211972A Kidney-tonifying composition and preparation method thereof |
| 07/24/2013 | CN103211836A Composition for treating osteoporosis |
| 07/24/2013 | CN103211773A Method for preparing leuprolide acetate microspheres |
| 07/24/2013 | CN103211764A Lipidosome combined with PYY analogue and preparation method thereof |
| 07/24/2013 | CN103211065A Pabular health tea electuary for promoting lead excretion |
| 07/24/2013 | CN102477069B Pro-Ala-Lys-Asp[OCH2(CH2)nCH3]-OCH2(CH2)nCH3, synthesizing method thereof, and application thereof as thrombolytic agent |
| 07/24/2013 | CN102477068B Amino acid derivative for preparing thrombus dissolving medicament, and preparation method and application thereof |
| 07/24/2013 | CN102471770B Antigen peptide and use thereof |
| 07/24/2013 | CN102388135B Protease for wound conditioning and skin care |
| 07/24/2013 | CN102352363B Scylla paramamosain antiviral type lipopolysaccharide resistant factor as well as preparation method and application thereof |
| 07/24/2013 | CN102083441B Use of nifurtimox for treating giardiasis |
| 07/24/2013 | CN101903050B Anisotropic implant and its method of production |
| 07/24/2013 | CN101688205B Anti-tumor drug, medicament, composition, and use thereof |
| 07/24/2013 | CN101669900B Polymeric delivery formulations of leuprolide with improved efficacy |
| 07/24/2013 | CN101616685B Unstructured recombinant polymers and uses thereof |
| 07/24/2013 | CN101503373B 2-amino-1-(4-nitro phenyl)-1-ethanol metalloid protease inhibitor, and preparation and use thereof |
| 07/24/2013 | CN101391103B Medicine composition for preventing and treating AIDS viral infection |
| 07/24/2013 | CN101384623B Process for the production of preformed conjugates of albumin and a therapeutic agent |
| 07/24/2013 | CN101370519B Combination of angiopoietin-2 antagonist and of VEGF-A, KDR and/or Flt1 antagonist for treating cancer |
| 07/23/2013 | US8492613 GNTIII expression in plants |
| 07/23/2013 | US8492530 Unstructured recombinant polymers and compositions comprising same |
| 07/23/2013 | US8492528 IL-B30 antibodies |
| 07/23/2013 | US8492523 Dragline protein |
| 07/23/2013 | US8492515 Antibacterial peptides active in systemic infections |
| 07/23/2013 | US8492366 E.g., salicylic acid, containing an alpha-hydroxy acid such as lactic, glycolic or citric acid |
| 07/23/2013 | US8492349 Analgesia with minimal tolerance and dependence by a mu opioid receptor agonist that also binds filamin A |
| 07/23/2013 | US8492348 Methods of increasing cerebral blood flow |
| 07/23/2013 | US8492347 Peptide for induction of immune tolerance as treatment for systemic lupus erythematosus |
| 07/23/2013 | US8492346 Methods of use of epsilon inhibitor compounds for the attenuation of pain |
| 07/23/2013 | US8492345 Cyclic peptide antitumor agents |
| 07/23/2013 | US8492343 Protein scaffold library based on kringle domain structure and uses thereof |
| 07/23/2013 | US8492342 Preprocalcitonin antigen T epitopes |
| 07/23/2013 | US8492341 Amyloid-β binding peptides |
| 07/23/2013 | US8492340 Methods of treating depression and other related diseases |
| 07/23/2013 | US8492339 Angiogenesis promoted by caged growth factors |
| 07/23/2013 | US8492338 Targeted therapeutic proteins |
| 07/23/2013 | US8492337 Targeted therapeutic proteins |
| 07/23/2013 | US8492336 Methods of treating neuropathic pain with an environ polypeptide |
| 07/23/2013 | US8492335 Platelet-derived growth factor compositions and methods for the treatment of tendinopathies |
| 07/23/2013 | US8492334 Sustained intraocular delivery of drugs from biodegradable polymeric microparticles |
| 07/23/2013 | US8492332 Oriented collagen-based materials, films and methods of making same |
| 07/23/2013 | US8492330 Formulation comprising GLP-1 |